Janus Henderson Group PLC Sells 3,373,056 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

Janus Henderson Group PLC trimmed its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 64.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,843,286 shares of the company's stock after selling 3,373,056 shares during the period. Janus Henderson Group PLC owned approximately 1.34% of Compass Therapeutics worth $3,364,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Rovin Capital UT ADV bought a new position in shares of Compass Therapeutics in the 3rd quarter valued at $25,000. Intech Investment Management LLC acquired a new stake in Compass Therapeutics in the third quarter valued at about $30,000. Cubist Systematic Strategies LLC bought a new position in Compass Therapeutics in the second quarter valued at about $41,000. Panagora Asset Management Inc. acquired a new position in Compass Therapeutics during the second quarter worth about $68,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company's stock worth $71,000 after acquiring an additional 5,515 shares during the last quarter. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Stock Down 9.6 %

Shares of CMPX stock traded down $0.16 during trading hours on Thursday, hitting $1.51. 572,142 shares of the company's stock traded hands, compared to its average volume of 440,754. Compass Therapeutics, Inc. has a 12 month low of $0.77 and a 12 month high of $2.34. The stock has a market cap of $207.76 million, a PE ratio of -4.08 and a beta of 0.89. The stock's 50 day simple moving average is $1.69 and its 200 day simple moving average is $1.41.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. As a group, equities research analysts expect that Compass Therapeutics, Inc. will post -0.35 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on CMPX shares. Leerink Partners lowered shares of Compass Therapeutics from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $5.00 to $4.00 in a report on Friday, November 15th. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 price target for the company in a report on Monday, September 16th. Leerink Partnrs cut Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 15th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Monday, November 11th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Compass Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $6.75.

Compass Therapeutics Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.